Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation

[1]  E. Gosmanova,et al.  Adherence to antihypertensive medications: is prescribing the right pill enough? , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  P. Gosse,et al.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial , 2015, The Lancet.

[3]  S. Oparil,et al.  New approaches in the treatment of hypertension. , 2015, Circulation research.

[4]  J. Václavík,et al.  Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension: Six-Month Results From the Prague-15 Study , 2015, Hypertension.

[5]  V. Hatzimanikatis,et al.  Antihypertensive Drugs Metabolism: An Update to Pharmacokinetic Profiles and Computational Approaches , 2014, Current pharmaceutical design.

[6]  W. Haverkamp,et al.  Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension , 2014, Journal of hypertension.

[7]  M. Caulfield,et al.  Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension , 2014, Heart.

[8]  T. Zelinka,et al.  Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? , 2014, Journal of Human Hypertension.

[9]  J. Svendsen,et al.  High incidence of secondary hypertension in patients referred for renal denervation – the Copenhagen experience , 2014, Blood pressure.

[10]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[11]  Nilesh J Samani,et al.  High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis , 2014, Heart.

[12]  B. Davis,et al.  Treatment resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2014 .

[13]  A. Dominiczak,et al.  Eligibility for Renal Denervation: Experience at 11 European Expert Centers , 2014, Hypertension.

[14]  D. Morisky,et al.  Pseudoresistant hypertension due to poor medication adherence. , 2014, International journal of cardiology.

[15]  C. Ayers,et al.  Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. , 2014, Journal of the American College of Cardiology.

[16]  S. Oparil,et al.  Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort , 2014, Hypertension.

[17]  N. Freemantle,et al.  Understanding Patients’ Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: A Meta-Analytic Review of the Necessity-Concerns Framework , 2013, PloS one.

[18]  Sandeep K. Krishnan,et al.  Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients. , 2013, American journal of hypertension.

[19]  S. Kjeldsen,et al.  Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension After Witnessed Intake of Medication Before Qualifying Ambulatory Blood Pressure , 2013, Hypertension.

[20]  E. Vink,et al.  Eligibility for percutaneous renal denervation: the importance of a systematic screening , 2013, Journal of hypertension.

[21]  S. Toennes,et al.  Resistant hypertension? Assessment of adherence by toxicological urine analysis , 2013, Journal of hypertension.

[22]  G. Bobrie,et al.  Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. , 2012, Journal of the American College of Cardiology.

[23]  G. Parati,et al.  ESH position paper: renal denervation - an interventional therapy of resistant hypertension. , 2012, Journal of hypertension.

[24]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[25]  Richard J McManus,et al.  NICE hypertension guideline 2011: evidence based evolution , 2012, BMJ : British Medical Journal.

[26]  J. Urquhart,et al.  Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. , 2012, Annual review of pharmacology and toxicology.

[27]  W. Elliott.  NICE clinical guideline 127: Hypertension: Clinical management of primary hypertension in adults , 2012 .

[28]  Symplicity Htn Investigators,et al.  Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months , 2011, Hypertension.

[29]  J. Banegas,et al.  Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.

[30]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[31]  C. Taira,et al.  Issues in drug metabolism of major antihypertensive drugs: β-blockers, calcium channel antagonists and angiotensin receptor blockers , 2010, Expert opinion on drug metabolism & toxicology.

[32]  J. Danaceau,et al.  Simultaneous extraction and screening of diuretics, beta-blockers, selected stimulants and steroids in human urine by HPLC-MS/MS and UPLC-MS/MS. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[33]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[34]  M. Mazzarino,et al.  A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, beta-adrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS , 2008, Analytical and bioanalytical chemistry.

[35]  John Urquhart,et al.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories , 2008, BMJ : British Medical Journal.

[36]  H. Ward,et al.  Predictive Validity of a Medication Adherence Measure in an Outpatient Setting , 2008, Journal of clinical hypertension.

[37]  J. S. Chatterjee,et al.  From compliance to concordance in diabetes , 2006, Journal of Medical Ethics.

[38]  A. Walker,et al.  Patient compliance in hypertension: role of illness perceptions and treatment beliefs , 2004, Journal of Human Hypertension.

[39]  T Fahey,et al.  Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings (Review) , 2018 .

[40]  AC Moffat,et al.  Clarke's analysis of drugs and poisons , 2003 .

[41]  Thomas G. Pickering,et al.  What is the white-coat effect and how should it be measured? , 2002, Blood pressure monitoring.

[42]  R. Fitzgerald,et al.  Broad spectrum drug identification directly from urine, using liquid chromatography-tandem mass spectrometry. , 1999, Clinical chemistry.

[43]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[44]  W. Grzeszczak,et al.  [The evaluation of hypertensive patients' adherence to the pharmacological treatment of hypertension]. , 1999, Wiadomosci lekarskie.